Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Veru Inc (VERU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VERU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25
1 Year Target Price $25
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.42% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.99M USD | Price to earnings Ratio 0.57 | 1Y Target Price 25 |
Price to earnings Ratio 0.57 | 1Y Target Price 25 | ||
Volume (30-day avg) 5 | Beta -0.71 | 52 Weeks Range 2.64 - 14.20 | Updated Date 08/14/2025 |
52 Weeks Range 2.64 - 14.20 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.05 | Actual -0.5 |
Profitability
Profit Margin -193.71% | Operating Margin (TTM) -227.14% |
Management Effectiveness
Return on Assets (TTM) -52.13% | Return on Equity (TTM) -106.02% |
Valuation
Trailing PE 0.57 | Forward PE 117.65 | Enterprise Value 38229098 | Price to Sales(TTM) 2.96 |
Enterprise Value 38229098 | Price to Sales(TTM) 2.96 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 14658400 | Shares Floating 12577838 |
Shares Outstanding 14658400 | Shares Floating 12577838 | ||
Percent Insiders 14.19 | Percent Institutions 26.36 |
Upturn AI SWOT
Veru Inc
Company Overview
History and Background
Veru Inc. (formerly known as Female Health Company) was founded in 1986. Initially focused on women's health, particularly the FC2 Female Condom, the company has expanded its pipeline to include treatments for prostate cancer and viral diseases.
Core Business Areas
- Oncology: Development and commercialization of therapies for prostate cancer, specifically enobosarm and sabizabulin.
- Infectious Disease: Development of sabizabulin for the treatment of viral diseases, including COVID-19 and influenza.
- Sexual Health: Commercialization of the FC2 Female Condom.
Leadership and Structure
Mitchell Steiner, M.D. serves as Chairman, President, and Chief Executive Officer. The company has a typical corporate structure with departments focused on research and development, clinical trials, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- FC2 Female Condom: A female-controlled barrier method for contraception and prevention of STIs. The company holds a significant market share in the female condom market, but faces competition from male condoms and other contraceptive methods. Revenue from this product is declining and has been estimated in the range of 5-10 million USD. Competitors include traditional male condoms (Trojan, Durex) and other female condom brands.
- Sabizabulin: An investigational oral drug for the treatment of COVID-19, influenza, and prostate cancer. Sabizabulin is not yet approved and doesn't have market share. Competitors are existing COVID-19, influenza and prostate cancer therapies.
- Enobosarm: An investigational oral selective androgen receptor modulator (SARM) in development for the treatment of prostate cancer. Enobosarm does not have market share. Competitors are existing prostate cancer therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments required in research and development, clinical trials, and regulatory approvals. The oncology and infectious disease segments are rapidly evolving due to technological advancements and unmet medical needs.
Positioning
Veru is a biopharmaceutical company focused on developing and commercializing novel therapies for oncology and infectious diseases. It aims to address unmet medical needs with oral therapies targeting specific mechanisms of action.
Total Addressable Market (TAM)
The total addressable markets for prostate cancer and viral diseases are substantial, reaching billions of dollars annually. Veru Inc. is positioned to capture a portion of these markets with successful development and commercialization of its pipeline products. Estimates can be found at various market research reports.
Upturn SWOT Analysis
Strengths
- Novel drug candidates (sabizabulin, enobosarm)
- Experienced leadership team
- Existing commercial infrastructure for FC2
- Targeting unmet medical needs
Weaknesses
- Dependence on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on regulatory approvals
- FC2 sales are declining
Opportunities
- Successful clinical trial results for sabizabulin and enobosarm
- Expansion into new markets and indications
- Partnerships with larger pharmaceutical companies
- FDA approval for sabizabulin in COVID-19 or influenza
Threats
- Clinical trial failures
- Competition from existing therapies and new entrants
- Regulatory hurdles
- Intellectual property challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- PFE
- JNJ
- GILD
Competitive Landscape
Veru faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Veru's success depends on demonstrating superior efficacy and safety of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by FC2 sales and investor interest in its drug pipeline. The company's growth has been inconsistent due to regulatory and clinical trial uncertainties.
Future Projections: Future growth depends heavily on the successful development and commercialization of sabizabulin and enobosarm. Analyst estimates vary widely based on the perceived likelihood of these events.
Recent Initiatives: Recent initiatives include advancing clinical trials for sabizabulin in COVID-19 and prostate cancer, and seeking regulatory approvals for these indications.
Summary
Veru Inc. is a biopharmaceutical company with a volatile past and a future highly dependent on the success of its drug pipeline. While it targets significant unmet medical needs in oncology and infectious diseases, its reliance on clinical trial outcomes and regulatory approvals presents substantial risks. The company's past focus on women's sexual health is now secondary to its pipeline programs. Investors should closely monitor clinical trial results and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Veru Inc. Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be made based on individual risk tolerance and financial circumstances. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veru Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1990-07-19 | Chairman, President & CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 210 | Website https://verupharma.com |
Full time employees 210 | Website https://verupharma.com | ||
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.